Effect of Shorten Gonadotropin-releasing Hormone Agonist Therapy on the Outcome of in Vitro Fertilization-Embryo Transfer in Patients With Endometriosis
Primary Purpose
Clinical Pregnancy Rate
Status
Unknown status
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Long term GnRH-a (3.75mg)
Sponsored by
About this trial
This is an interventional treatment trial for Clinical Pregnancy Rate focused on measuring endometriosis, long term GnRH-a
Eligibility Criteria
Inclusion Criteria:
- first IVF cycle;
- with normal ovarian reserve(FSH(10miu/ml; antral follicle count )3)
- with normal uterine
Exclusion Criteria:
- Pre-implantation genetic diagnosis cycles;
- Oocyte donation cycles
Sites / Locations
- Reproductive Medical Center, First Affiliated Hospital of Zhengzhou UniversityRecruiting
Arms of the Study
Arm 1
Arm 2
Arm Type
Active Comparator
Experimental
Arm Label
Long term GnRH-a for 1 month
patient in this group only receive GnRH-a 3.75 for 2 month
Arm Description
patient in this group only receive GnRH-a 3.75 for 1 month
patient in this group only receive GnRH-a 3.75 for 2 month
Outcomes
Primary Outcome Measures
clinical pregnancy rate
Secondary Outcome Measures
Number of oocytes retrieved
2 pronucleus(2PN)fertilization rate
Number of 2PN/Matured oocytes
Full Information
NCT ID
NCT03006406
First Posted
December 28, 2016
Last Updated
December 29, 2016
Sponsor
The First Affiliated Hospital of Zhengzhou University
1. Study Identification
Unique Protocol Identification Number
NCT03006406
Brief Title
Effect of Shorten Gonadotropin-releasing Hormone Agonist Therapy on the Outcome of in Vitro Fertilization-Embryo Transfer in Patients With Endometriosis
Study Type
Interventional
2. Study Status
Record Verification Date
December 2016
Overall Recruitment Status
Unknown status
Study Start Date
January 2016 (undefined)
Primary Completion Date
January 2017 (Anticipated)
Study Completion Date
January 2018 (Anticipated)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The First Affiliated Hospital of Zhengzhou University
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
Gonadotropin-releasing hormone analogue (GnRH-a) is a synthetic decapeptide compound which can down-regulate pituitary function causing a temporary low estrogen state. Since endometriosis is an estrogen-dependent disease, the use of long-acting GnRH-a can control the growth of endometriosis by inhibiting ovary function.Some scholars have found that, for adenomyosis patients who received a super long protocol (pretreatment of long-acting GnRH-a for 1-2 months) in IVF treatment, the pregnancy outcome is comparable to that of the controls with normal uterus. Thus, the aim of this study is to compare the clinical pregnancy rate in patients treated with GnRH-a for 1, or 2 months.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Clinical Pregnancy Rate
Keywords
endometriosis, long term GnRH-a
7. Study Design
Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
50 (Anticipated)
8. Arms, Groups, and Interventions
Arm Title
Long term GnRH-a for 1 month
Arm Type
Active Comparator
Arm Description
patient in this group only receive GnRH-a 3.75 for 1 month
Arm Title
patient in this group only receive GnRH-a 3.75 for 2 month
Arm Type
Experimental
Arm Description
patient in this group only receive GnRH-a 3.75 for 2 month
Intervention Type
Drug
Intervention Name(s)
Long term GnRH-a (3.75mg)
Intervention Description
patient in this group only receive GnRH-a 3.75 for pituitary down-regulation
Primary Outcome Measure Information:
Title
clinical pregnancy rate
Time Frame
5 weeks after embryo transfer
Secondary Outcome Measure Information:
Title
Number of oocytes retrieved
Time Frame
1 day at oocyte retrieved day
Title
2 pronucleus(2PN)fertilization rate
Description
Number of 2PN/Matured oocytes
Time Frame
48hours after oocyte retrieved day
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
22 Years
Maximum Age & Unit of Time
42 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
first IVF cycle;
with normal ovarian reserve(FSH(10miu/ml; antral follicle count )3)
with normal uterine
Exclusion Criteria:
Pre-implantation genetic diagnosis cycles;
Oocyte donation cycles
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Huijuan Kong, M.D.
Phone
86-371-67966161
Email
luckyjuanjuan819@126.com
Facility Information:
Facility Name
Reproductive Medical Center, First Affiliated Hospital of Zhengzhou University
City
Zhengzhou
State/Province
Henan
ZIP/Postal Code
450052
Country
China
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Yingpu Ms Sun, M.D,PhD
Phone
86-13803841888
Email
syp2008@vip.sina.com
First Name & Middle Initial & Last Name & Degree
Zhiqin Mr Bu, MD
Phone
86-15981978863
Email
rmczzu@126.com
12. IPD Sharing Statement
Plan to Share IPD
Undecided
Citations:
PubMed Identifier
24262434
Citation
van der Houwen LE, Mijatovic V, Leemhuis E, Schats R, Heymans MW, Lambalk CB, Hompes PG. Efficacy and safety of IVF/ICSI in patients with severe endometriosis after long-term pituitary down-regulation. Reprod Biomed Online. 2014 Jan;28(1):39-46. doi: 10.1016/j.rbmo.2013.09.027. Epub 2013 Oct 9.
Results Reference
background
PubMed Identifier
20409633
Citation
Mijatovic V, Florijn E, Halim N, Schats R, Hompes P. Adenomyosis has no adverse effects on IVF/ICSI outcomes in women with endometriosis treated with long-term pituitary down-regulation before IVF/ICSI. Eur J Obstet Gynecol Reprod Biol. 2010 Jul;151(1):62-5. doi: 10.1016/j.ejogrb.2010.02.047. Epub 2010 Apr 21.
Results Reference
background
PubMed Identifier
30572916
Citation
Kong H, Hu L, Nie L, Yu X, Dai W, Li J, Chen C, Bu Z, Shi H, Wu Q, Guan Y, Sun Y. A multi-center, randomized controlled clinical trial of the application of a shortened protocol of long-acting Triptorelin down-regulated prior to IVF/ICSI among patients with endometriosis: A protocol. Reprod Health. 2018 Dec 20;15(1):213. doi: 10.1186/s12978-018-0639-8.
Results Reference
derived
Learn more about this trial
Effect of Shorten Gonadotropin-releasing Hormone Agonist Therapy on the Outcome of in Vitro Fertilization-Embryo Transfer in Patients With Endometriosis
We'll reach out to this number within 24 hrs